<DOC>
	<DOCNO>NCT00446082</DOCNO>
	<brief_summary>This study assess pharmacokinetic profile safety/tolerability profile single monthly dos pasireotide LAR intramuscular ( i.m . ) injection patient acromegaly patient carcinoid disease</brief_summary>
	<brief_title>Study Pasireotide Long Acting Release ( LAR ) Injection Patients With Acromegaly Patients With Carcinoid Disease</brief_title>
	<detailed_description />
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<criteria>Inclusion criterion patient acromegaly : Male female patient 18 80 year Patients acromegaly due pituitary adenoma elevate GH IGF1 concentration Exclusion criterion patient acromegaly : Patients compression optic chiasm cause visual field defect Specific criterion apply patient receive certain type therapy radiotherapy , surgery , chemo immunotherapy month prior study start Female patient pregnant lactate Inclusion criterion patient carcinoid disease : Male female patient age â‰¥18 year Patients histologically confirm , metastatic carcinoid tumor digestive system Patients elevation chromograninA ( CgA ) and/or serotonin Patients adequately control somatostatin analogue Exclusion criterion patient carcinoid disease : Specific criterion apply patient receive certain type therapy radiotherapy , surgery , chemo immunotherapy month prior study start Female patient pregnant lactate Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Refractory/ resistant carcinoid disease</keyword>
	<keyword>acromegaly</keyword>
	<keyword>adult</keyword>
	<keyword>pasireotide LAR</keyword>
	<keyword>somatostatin analogue</keyword>
	<keyword>SOM230</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Refractory resistant carcinoid disease acromegaly</keyword>
</DOC>